A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

NCT07416695 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

SCLC
NEC

Interventions

DRUG: HLX3901

Sponsor

Shanghai Henlius Biotech